Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

iwMDS 2026 | Advances in the diagnosis, classification & prognostication of MDS

In this roundtable discussion, Valeria Santini, MD, University of Florence, Florence, Italy, Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, Arjan van de Loosdrecht, MD, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands, Tariq Kewan, MD, Mayo Clinic, Rochester, MN, and Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, discuss advances in the diagnosis and prognostication of myelodysplastic syndromes (MDS). Dr Efficace highlights the importance of harmonizing how MDS clinical trials assess patient-reported outcomes, while Dr Della Porta discusses the potential of artificial intelligence to generate dynamic prognostic scores. Prof. van de Loosdrecht comments on standardizing flow cytometry and integrating it into MDS classification, and Dr Kewan addresses the unmet need in TP53-mutated MDS and the role of emerging technologies in identifying patient subsets. This roundtable discussion took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Valeria Santini:

Hi, my name is Valeria Santini. I work at the University of Florence in Italy. And today we are going to discuss what was presented during the session touching upon diagnosis, prognostication of myelodysplastic syndromes with different aspects of it. So different points of view, different methods. And I think I can introduce my colleagues that were with me from the session...

Valeria Santini:

Hi, my name is Valeria Santini. I work at the University of Florence in Italy. And today we are going to discuss what was presented during the session touching upon diagnosis, prognostication of myelodysplastic syndromes with different aspects of it. So different points of view, different methods. And I think I can introduce my colleagues that were with me from the session.

Matteo Della Porta:

Hello, my name is Matteo Della Porta from Humanitas Research Hospital in Milan, Italy.

Arjan Van De Loosdrecht:

I’m Arjan Van De Loosdrecht, hematologist at the Amsterdam University in the Netherlands.

Tariq Kewan:

Hello, my name is Tariq Kewan. I’m a hematologist from Mayo Clinic, Rochester, USA.

Fabio Efficace:

Hi, I’m Fabio Efficace from the Italian Group for Haematologic Disease in Italy.

Valeria Santini:

Okay, as I mentioned, the discussion and the session was very, let’s say, lively and showing very different hot topics in prognostication and diagnosis of MDS. So I would like to start with Fabio asking you the point of view of patients is becoming more and more important. So for our efforts to improve the quality of life, the survival of patients, it’s extremely relevant to know what the patients think and how do they feel while we are trying to cure them?

Fabio Efficace:

Yeah, absolutely. I mean, the patient view is pretty unique and it’s so important that in clinical trials, we also assess the patient perspective via these patient-reported outcome questionnaires. And even because we are facing an evolving treatment scenario in MDS, so it’s important that we balance clinical efficacy with the effect on the patient’s life. And during my presentation, I was stressing the importance of harmonizing the way we assess patient-reported outcomes in clinical trials in MDS and the effort made by the international community to standardize this process and to come up with a common metric based on which we can assess this across trials in MDS.

Valeria Santini:

That is very interesting. But on the other end of the story, we have artificial intelligence that may include also what the patient thinks, but also all the molecular clinical data. So, Matteo, can you please comment on the possibility of merging or the aspect of diagnosis and come to a conclusion?

Matteo Della Porta:

Yes. During this session, we also try to discuss how we can implement new technologies with a specific reference to artificial intelligence into the clinical workup of the patient with MDS. And I think that one of the most important points is that artificial intelligence can refine our capability to capture prognostic information at an individual patient level. The prognostic assessment of MDS is really important because we are facing a varied heterogeneous population of patients with a different natural history of the disease and a correct prognostic certification is a basis for an effective treatment allocation. Artificial intelligence can be useful especially when we are trying to introduce the concept of a dynamic evaluation of the prognosis of the patient. We know that MDS is characterized by the phenomenon of clonal evolution. That means that the genomic landscape of an MDS patient is evolving. So we have to move from an assessment of the molecular profile of the patient that is conventionally provided only at the time of diagnosis to a concept of molecular monitoring of the patient. And there is currently a huge effort from the clinical and scientific international MDS community to define a way in order to integrate this kind of longitudinal assessment of clinical and molecular parameters into a next-generation prognostic score based on artificial intelligence to refine the prognostication of MDS and possibly to improve the capability to provide the right decision in terms of treatment as well as to define the optimal timing of therapeutic intervention.

Valeria Santini:

So molecular assessment is super important. The integration of clinical and molecular longitudinal data are important. But if we step a little bit back, we have to diagnose as MDS. So Arjan has been working for many years to implement morphology with flow cytometry. And in the new classification of MDS, this will be implemented really in the definition of MDS. Can you comment a little bit on this?

Arjan Van De Loosdrecht:

Thank you, Valeria, for stressing this important issue. So it starts all with the diagnosis. And we are facing on a daily basis that it is not always easy to have the diagnosis or to make an appropriate diagnosis. And what we have done, we try to better understand how the abnormal hematopoiesis reflects differences in expression levels of proteins on the cell level. That’s flow cytometry. And the first problem we encountered was standardization of the technology. And after a lot of multicenter trials and independent validation cohorts, we were happy now to have a robust technology which can now apply it to the diagnostic workup. And we translated all those potentially important markers to a standardized panel and now the community is convinced that in cases where the microscope is not fully clear about the amount of dysplasia, or is it really dysplasia, to call it MDS, to add with this new technology. And the WHO, or the advice to the new classification of diseases, adopted now this approach. Now the next step is to make it really simple. It is already robust, but to make it happen to all pathologists and clinicians to do the assay, but also to the right interpretation.

Valeria Santini:

Yeah, so give some help to really implement and use the recommendations in all the labs.

Arjan Van De Loosdrecht:

But at the end, it’s quite clear that we go to an integrated report that says we need the microscope, we need the flow cytometer, we need conventional cytogenetics as well as the molecular background. And that makes together the diagnosis of MDS with then also inherent prognostic information, which is the next step.

Valeria Santini:

Yes, you used the right word. We have to have an integrated system to give the real diagnosis and prognosis of these patients. And to come to Tariq, the hot topic and the Achilles’ heel of all hematologists is addressing therapy and diagnosis of MDS with TP53 mutations.

Tariq Kewan:

Thank you, Dr. Santini. I agree. I think this continues to be, as I said, the heart of the unmet need because regardless of all the conventional treatment we do have, including allogenic transplantation, patients with TP53 continue to have poor prognosis. And it’s a unique type of molecular spectrum because we know that we can assess allelic status, but still we have a little bit of discrepancy in classification between the ICC and WHO in determining which patients are bi-allelic and monoallelic. I tried to focus on studies done in order to discriminate patients who might have better prognosis in this unmet need. And I’ve shown some results that VAF, a surrogate marker for the allelic status, was able to identify some patients with better prognosis, mainly the ones with low blast MDS and VAF less than 19% or around like, you know, 20%. But I really think like, you know, as the field is moving forward, we need more technology such as flow cytometry, maybe looking at digital pathology, or even like single-cell sequencing in order to be able to understand the function of TP53 and try to identify subsets of patients that might respond differently to different treatment, including allogenic transplant. And then, as Dr Della Porta mentioned, providing the appropriate therapy for the appropriate patients.

Valeria Santini:

Yeah. And one important thing is that variant allele frequency is extremely important, but there is not a standard method in all the labs. So this is still to be polished, I think, and improved. But your data were extremely important to understand that not what looks the same is in fact behaving in the same clinical way. So I think that we had, as I mentioned in the beginning, we had several points of view, several approaches that will hopefully help us to understand better how to treat our patients. Thank you.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.